Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2020-11-02 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva annonce la sélection de deux nouveaux abstracts « late-breaking » lors du The Liver Meeting Digital Experience™ 2020 organisé par l’AASLD
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva, dated November 2, 2020, announcing the selection of two 'late-breaking' abstracts and one regular abstract for presentation at 'The Liver Meeting Digital Experience™ 2020' organized by the AASLD. It details the titles, presentation types (poster and oral plenary session), and content related to their drug lanifibranor for NASH treatment. This type of announcement, detailing upcoming scientific presentations, data releases, or participation in industry conferences, is characteristic of investor relations or general corporate news, but it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is an announcement about scientific data presentation and participation in a medical conference, it fits best under general Investor Relations or a specific announcement category. Given the options, it is a corporate announcement regarding scientific progress and investor communication, but it doesn't fit the specific definitions for ER, IR, or CT. It is a general corporate update about scientific findings being presented. Since it is not a formal financial report, nor a management change, nor a dividend notice, and it is not explicitly announcing the *release* of a major report (which would be RPA), the most appropriate general category for this type of scientific/investor update, which is not covered by the highly specific financial codes, is the general Regulatory Filings/Announcements category (RNS), or potentially Investor Presentation (IP) if it were the presentation itself, but this is the *announcement* of the presentation. Given the context of a press release detailing scientific data presentation at a conference, RNS (Regulatory Filings/Miscellaneous Announcements) is the best fit as a catch-all for non-standard, yet important, corporate news.
2020-11-02 French
Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020
Legal Proceedings Report Classification · 99% confidence The document is an announcement from Inventiva dated November 2, 2020, detailing the acceptance of several abstracts (including late-breaking ones) for poster and oral presentations at the AASLD The Liver Meeting Digital Experience™ 2020. It provides details about the content of these presentations (clinical trial data for lanifibranor) and includes general information about the company, the drug, and the trial. This format—a press release announcing scientific data presentation at a conference—is characteristic of an Investor Presentation (IP) or a general corporate update, but since it is specifically announcing the presentation of clinical data and results summaries, it aligns best with the 'Investor Presentation' category, which often includes such scientific updates, or potentially an 'Earnings Release' if it were tied to a reporting period, but here it is clearly focused on conference data dissemination. Given the detailed breakdown of abstracts and the mention of a KOL webcast that can be followed in the 'Investors – Investor Presentations' section, 'IP' (Investor Presentation) is the most fitting classification for this type of scientific/clinical data dissemination aimed at investors.
2020-11-02 English
Inventiva organisera un webcast avec des leaders d’opinion à l’occasion du The Liver Meeting Digital Experience™ 2020 de l’AASLD
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "PRESS RELEASE COMMUNIQUE DE PRESSE" and announces a future event: a webcast featuring KOLs discussing Phase IIb NATIVE trial results for lanifibranor at 'The Liver Meeting Digital Experience™ 2020' organized by AASLD. It provides the date, time, connection details for the webcast, and background information on the drug and the study. This structure—announcing an upcoming event where results or presentations will be shared, rather than containing the full results or a formal regulatory filing—strongly indicates an announcement about an investor/analyst event. Since it is an announcement about a presentation/discussion of clinical data and strategy, the most fitting category is Investor Presentation (IP), as it is promoting content that will be presented to investors, even if the primary vehicle is a webcast rather than a static deck. However, the document itself is a press release announcing the *event* and the *availability* of the presentation materials later ('Le document de présentation et le lien vers le webcast (en direct et en replay) seront également disponibles...'). This aligns closely with a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS) if the content were less specific. Given the focus on an upcoming presentation of clinical data and strategy to investors, 'Investor Presentation (IP)' is a strong fit for the *subject matter*, but 'Report Publication Announcement (RPA)' fits the *format* of announcing the availability of future presentation materials. Since the content details the specific presentations that will occur, it functions as a preview/announcement for investor engagement, making IP slightly more descriptive of the intent than RPA, which is often used for announcing the release of a formal report (like a 10-K). Given the context of a press release announcing a detailed webcast presentation of clinical trial results and market overview, IP is the best fit for the substance being promoted.
2020-10-28 French
Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces an upcoming event (a KOL webcast) related to clinical trial results, rather than presenting the full financial report itself. It details the agenda, speakers, and connection details for the event. While it discusses clinical trial data and mentions financial reports (Universal Registration Document, half-year financial report) in the disclaimer section, the primary purpose of this specific document is to announce an investor/KOL event. This fits best under the category of an announcement related to investor relations or a general regulatory filing, but since it is a specific announcement about an event where results will be presented, it is most closely aligned with an Investor Presentation (IP) announcement or a general Regulatory Filing (RNS). Given the content is an announcement about a presentation/webcast featuring clinical data and KOL discussions, 'Investor Presentation (IP)' is a strong candidate, but since it is a press release announcing the *event* and not the presentation document itself, and it doesn't fit the specific definitions of ER, AR, or 10-K, the most appropriate general category for a corporate announcement of this nature that isn't a direct financial result release (ER) or a proxy statement (DEF 14A) is often RNS, or potentially IP if the presentation material is the focus. However, the document is a press release announcing a future event where data will be discussed, which is a common precursor to an Investor Presentation or a general corporate update. Given the options, and recognizing it's a formal announcement of corporate activity (a webcast event), RNS (Regulatory Filings - general fallback) is safe, but since it is specifically about presenting data to investors/KOLs, IP is also plausible if we interpret it as the announcement *for* an investor presentation. Since it is a press release announcing a future event, and not the presentation document itself, and it is not a standard earnings release (ER), I will classify it as a general Regulatory Filing (RNS) as it is a broad corporate announcement. Revisiting the definitions: It is not an ER (initial results announcement), nor an IR (comprehensive interim report). It is an announcement about a future presentation. This type of announcement often falls under RNS or sometimes IP if the presentation material is the main focus. Since the document is a press release announcing the *event* and not the presentation material itself, RNS is the most appropriate fallback for a non-standard announcement.
2020-10-28 English
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Inventiva received FDA Fast Track designation for its drug candidate odiparcil. It details the implications of this designation and provides background information on the drug and the company. This format—a formal announcement of a specific corporate/regulatory event (FDA designation) via a press release—does not fit the definitions for a comprehensive financial report (10-K, IR, MRQ), a management discussion (MDA), or a specific regulatory filing like DIRS or DIV. It is a general corporate update. Since it is a press release announcing a significant development, and it doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate general category for a significant, non-financial-result-focused regulatory/development update that is not a standard SEC filing is the fallback category, Regulatory Filings (RNS), as it serves as a general regulatory announcement channel for the company.
2020-10-19 English
Inventiva obtient le statut « Fast Track » de la FDA pour son candidat médicament au stade clinique odiparcil dans la MPS
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Inventiva's drug candidate, odiparcil, received "Fast Track" status from the FDA for treating MPS VI. This is a specific, time-sensitive announcement regarding regulatory progress and clinical development milestones, rather than a comprehensive periodic financial report (like 10-K or IR) or a transcript of a call. It fits best under the category of a general regulatory or corporate announcement. Since it is a press release announcing a specific regulatory event (FDA status), it is not a standard Earnings Release (ER) or a comprehensive Interim Report (IR). Given the options, it is a specific corporate update. While it relates to regulatory progress, it is not a filing itself, but an announcement about regulatory interaction. It is most closely aligned with a general corporate announcement, which often falls under Regulatory Filings (RNS) if a more specific category like ER or CT is not applicable. However, since it is a press release detailing a significant corporate/regulatory event, and not a standard financial report, RNS is the most appropriate fallback for a non-standard, non-financial-statement announcement.
2020-10-19 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.